斯帕森坦在中国上市了吗?好购买吗？

Sparsentan is a new drug used to treat primary immunoglobulin A nephropathy. It slows down the decline of renal function by antagonizing endothelin and angiotensin II receptors. Currently, the drug has been approved for marketing in the United States, but the marketing and purchase situation in China still requires attention. This article will analyze the listing status, purchase channels and medical insurance coverage of Sparsentin in China.

Is sparsentane available on the market in China

It is an innovative drug, and its launch in the Chinese market has attracted much attention. The following analyzes its current situation from two aspects: approval progress and clinical application.

Approval Progress

As of March 2025, Sparsentin has not yet been officially approved for marketing in China. Public information from China’s National Medical Products Administration (NMPA) shows that the drug is still in the clinical evaluation or approval stage. If domestic patients want to use it, they may need to go through special channels or participate in clinical trials.

Clinical Application Status

At present, some hospitals in China may introduce sparsentan through international cooperation or special applications, but the scope of application is limited. Patients need to evaluate the necessity of medication under the guidance of a doctor and pay attention to official approval updates.

The launch of sparsentin in China still needs to wait for further official notification. Patients can obtain the latest information through regular medical institutions.

Is Sparsentan easy to buy?

Since Sparsentan has not yet been launched in China, the purchasing channels are relatively limited. It is usually not available directly in domestic hospitals or pharmacies and needs to be obtained through other channels.

Overseas drug purchase channels

Some patients may obtain sparsentin through overseas medical treatment, overseas drug purchase, or cross-border medical platforms, but they need to pay attention to the authenticity of the drug and transportation risks. U.S. pharmacies require a prescription and are more expensive, which may not be suitable for long-term medication needs.

Clinical trial participation

If relevant clinical trials are carried out in China, patients can obtain the opportunity to use sparsentane by signing up, but they must meet strict enrollment conditions.

Medical service institutions

Domestic formal medical service institutions may help purchase sparsentin and obtain the drug through direct mail, which is more convenient.

To purchase sparsentin, you need to choose the channel carefully, giving priority to formal medical institutions or official cooperation projects.

Is Sparsentan included in the national medical insurance?

Sparsentan is currently not included in China's national medical insurance directory. The following analyzes its medical insurance status and patient cost burden.

Medical insurance coverage

Since the drug is not marketed in China, it is naturally not included in the scope of medical insurance reimbursement. Patients need to pay for it in full, which puts great financial pressure on them.

Future possibilities

If sparsentin is approved for marketing in the future, it may be included in the medical insurance directory through negotiation. However, drug efficacy, price and the affordability of medical insurance funds need to be comprehensively considered.

Under the current situation of not being covered by medical insurance, patients need to plan their medication budget in advance, or pay attention to assistance projects such as charitable drug donations.